Phase 1b/2a trial of the superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavity or oropharyngeal carcinoma

Carryn M Anderson
University of Iowa

Stephen T Sonis
Dana-Farber Cancer Institute

Christopher M Lee
Cancer Care Northwest

Douglas Adkins
Washington University School of Medicine in St. Louis

Bryan G Allen
University of Iowa

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Clinical Investigation

Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma

Carryn M. Anderson, MD,* Stephen T. Sonis, DMD, DMSc,‡ Christopher M. Lee, MD,§ Douglas Adkins, MD,‡ Bryan G. Allen, MD, PhD,* Wenzing Sun, MD, PhD,* Sanjiv S. Agarwala, MD,¶ Madhavi L. Venigalla, MD,¶ Yuhchyau Chen, MD, PhD,§ Weining Zhen, MD,** Diane R. Mould, PhD,†† Jon T. Holmlund, MD,††† Jeffrey M. Brill, BS,††† and John M. Buatti, MD*

*Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa; ‡Biomodels and Division of Oral Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts; §Cancer Care Northwest, Spokane, Washington; ¶Section of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri; †Department of Medical Oncology, St. Luke’s University Hospital and Temple University, Easton, Pennsylvania; ‡Lakeland Regional Health Cancer Center, Lakeland, Florida; †Department of Radiation Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, New York; **Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska; ¿Projections Research Inc., Phoenixville, Pennsylvania; and ††Galera Therapeutics, Inc., Malvern, Pennsylvania

Summary

Severe oral mucositis is a critical problem in patients

Purpose: To assess the safety of the superoxide dismutase mimetic GC4419 in combination with radiation and concurrent cisplatin for patients with oral cavity or oropharyngeal cancer (OCC) and to assess the potential of GC4419 to reduce severe oral mucositis (OM).

Reprint requests to: Carryn M. Anderson, MD, Department of Radiation Oncology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, 01614 PF PW, Iowa City, IA 52242. Tel: (319) 353-8836; E-mail: carryn-anderson@uiowa.edu

The results of this study were presented in part at the Multidisciplinary Head and Neck Cancer Symposium (oral presentation), February 18-20, 2016, Scottsdale, AZ; the American Society of Clinical Oncology Annual Meeting (poster discussion), June 3-7, 2016, Chicago, IL; and the 58th Annual Meeting of the American Society for Radiation Oncology (oral presentation), September 24-28, 2016, Boston, MA.

This study was funded by Galera Therapeutics, Inc.

Conflict of interest: J.M.B and J.T.H are employees of Galera Therapeutics, Inc and holders of stock options.

Acknowledgments—The authors thank Charles Kunos, MD, PhD, and Larisa Greenberg, MD, for their contributions to patient enrollment; Curtis Miyamoto, MD, for providing independent review of the intensity modulated radiation therapy plans for enrolled patients; the Free Radical and Radiation Biology Research Core at University of Iowa for sample preparation and handling; Robert Beardsley and Art Fratamico for their helpful comments about the manuscript; and Gareth Smith for his assistance in preparing the manuscript.
receiving chemoradiation for oral cavity and oropharynx cancer. This phase 1/2 dose and duration escalation study tested the safety of a daily 60-minute pre-RT infusion of GC4419, a superoxide dismutase mimetic. A maximum tolerated dose was not reached, safety was acceptable (nausea/vomiting and facial paresthesia during infusion appeared GC4419 dose—related), and doses of 30 and 90 mg/d for the duration of radiation were selected for further study.

**Patients and Methods:** Patients with locally advanced OCC treated with definitive or postoperative intensity modulated radiation therapy (IMRT) plus cisplatin received GC4419 by 60-minute intravenous infusion, ending <60 minutes before IMRT, Monday through Friday for 3 to 7 weeks, in a dose and duration escalation study. Oral mucositis was assessed twice weekly during and weekly after IMRT.

**Results:** A total of 46 patients received GC4419 in 11 separate dosing and duration cohorts: dose escalation occurred in 5 cohorts receiving 15 to 112 mg/d over 3 weeks (n = 20), dose escalation in 3 cohorts receiving 112 mg/d over 4 to 6 weeks (n = 12), and then 3 additional cohorts receiving 30 or 90 mg/d over 6 to 7 weeks (n = 14). A maximum tolerated dose was not reached. One dose-limiting toxicity (grade 3 gastrointestinal enteritis and vomiting with hyponatremia) occurred in each of 2 separate cohorts at 112 mg. Nausea/vomiting and facial paresthesia during infusion seemed to be GC4419 dose—related. Severe OM occurred through 60 Gy in 4 of 14 patients (29%) dosed for 6 to 7 weeks, with median duration of only 2.5 days.

**Conclusions:** The safety of GC4419 concurrently with chemoradiation for OCC was acceptable. Toxicities included nausea/vomiting and paresthesia. Doses of 30 and 90 mg/d administered for 7 weeks were selected for further study. In an exploratory analysis, severe OM seemed less frequent and briefer than expected. © 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

**Introduction**

Oral mucositis (OM) is a common, disruptive, and painful complication of radiation and chemoradiation (CRT) for head and neck squamous cell carcinoma (HNSCC) (1). Approximately 70% of patients receiving CRT for oral cavity or oropharyngeal cancer (OCC) develop severe OM, defined as grade 3 to 4 by the World Health Organization (WHO) scale (2, 3). Oral mucositis causes marked pain requiring narcotic analgesics and adversely affects nutrition, hydration, speech, swallowing, quality of life, bacteremia risk, and feeding tube placement and use rates (4, 5). Severe OM is also associated with radiation treatment breaks, which harms successful tumor management (6-8). The financial cost of managing patients with severe OM is substantial and is attributable to increased hospitalization and emergency room use (9, 10).

Recommended approaches to managing OM are limited to palliation and pain control with topical agents and systemic analgesics (11-19). The only approved drug or biological to reduce OM, palifermin, is limited to patients at risk for OM associated with conditioning regimens before stem cell transplant for the treatment of hematologic malignancies (20, 21).

The pathogenesis of mucositis is a complex sequence of biologic events in which oxidative stress plays a pivotal initiating role (22). Therapeutic radiation causes radiolytic hydrolysis and the formation of reactive oxygen species, including superoxide anion (O2\(^•−\)). Superoxide is extremely reactive, triggering a cascade of signaling pathways in the cells and tissues of the submucosa and resulting in apoptosis of epithelial stem cells, consequent loss of epithelial renewal, atrophy, and mucosal ulceration (23).

A complement of naturally occurring superoxide dismutase (SOD) enzymes exists to dispose of superoxide (24). However, large, rapidly produced amounts of superoxide due to therapeutic radiation can overwhelm these native SOD enzymes. GC4419 is a highly stable manganese-containing macrocyclic complex (molecular weight = 483), whose activity mimics the native enzymes, selectively removing superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite. An active enantiomer of GC4419 protected mice from lethal total body irradiation (25) and reduced radiation-induced OM in a hamster cheek pouch model in a dose-related fashion (26). GC4419 had equivalent effects in the same OM model but did not spare tumor from the effects of CRT in multiple preclinical models (Galera Therapeutics, unpublished data). Further, GC4419 protected mice from radiation-induced pulmonary fibrosis (27).

The present study was done to assess the safety of GC4419 in combination with radiation and concurrent cisplatin for patients with OCC and to assess the potential of GC4419 to reduce severe OM.

**Patients and Methods**

**Patients**

Eligible patients had oral cavity or oropharyngeal, stage III-IVb HNSCC, Eastern Cooperative Oncology Group performance status ≤ 2, and a treatment plan that called for standard fractionation intensity modulated radiation therapy (IMRT) with concurrent cisplatin (80-100 mg/m\(^2\) every 3 weeks or
30-40 mg/m² weekly). The IMRT plan had to include at least 2 oral mucosal sites (right or left buccal mucosa, right or left ventral/lateral oral tongue, floor of mouth, or soft palate) within the cumulative 50-Gy isodose line. The IMRT plans were centrally reviewed by an independent radiation oncologist to confirm adherence to protocol requirements. Adequate marrow, renal, and hepatic functions were required. Prophylactic percutaneous endoscopic gastrostomy tube placement was allowed at enrollment. Patients were excluded if they had prior induction chemotherapy, significant dietary compromise due to reduced oral/pharyngeal function, or concurrent treatment with nitrates.

The protocol was approved by each institution’s institutional review board and was registered at ClinicalTrials.gov. Investigators obtained written informed consent from each participant. Data were anonymized to protect the study subjects’ identities.

**Treatment and study design**

Integrity modulated radiation therapy was administered once daily, Monday-Friday, at 2.0 to 2.2 Gy/d, to a cumulative tumor dose between 60 and 72 Gy. The assigned dose of GC4419 was delivered intravenously in normal saline over 60 minutes, ending within 60 minutes before each radiation fraction. Oral rinses limited to sodium bicarbonate, lidocaine, and antifungal agents were permitted. Other concurrent available or experimental systemic or topical pharmaceuticals or devices, or low-level laser therapy, were excluded. Supportive care per American Society of Clinical Oncology guidelines, including antiemetic drugs for cisplatin, was encouraged.

The study followed a serial cohort dose-escalation design with 3 to 6 patients enrolled per cohort. The first 5 cohorts received GC4419 before each of the first 14 IMRT fractions (over approximately 3 weeks), reflecting the duration of Investigational New Drug Application-supporting animal toxicology studies of GC4419. These 5 serial cohorts received 15, 30, 50, 75, or 112 mg of GC4419 per dose. These doses were based on previous results with a single 15-minute infusion administered to healthy human volunteers; the 60-minute infusion duration was chosen because dogs tolerated higher doses administered more slowly (ie, 12.5 mg/kg over 60 minutes vs 5 mg/kg over 15 minutes [Galera Therapeutics, unpublished observations]). On the basis of observed safety results in the first 5 cohorts, the protocol was then amended to allow “duration extension” of GC4419 administered progressively longer during IMRT. Three serial cohorts received 112 mg of GC4419 before IMRT for 4, 5, or 6 weeks. Subsequent review of safety and OM results through these cohorts led to a decision by the sponsor to add 3 cohorts to extend dosing further at reduced doses: 90 mg for 6 or 7 weeks or 30 mg for 7 weeks.

Dose-limiting toxicity (DLT) was defined as follows: grade 3 or 4 nausea or vomiting despite maximal antiemetic therapy; grade 4 anemia; grade 4 thrombocytopenia or grade 3 associated with hemorrhage; grade 4 neutropenia lasting >7 days; grade 3 or 4 febrile neutropenia; or other grade 3+ events (except oral mucositis), judged by the investigator not attributable to IMRT, cisplatin, or complications of HNSCC. For adverse events attributable to IMRT or cisplatin but judged to be exacerbated by the presence of GC4419, dose modification of GC4419 was at the investigator’s discretion. For any given patient, DLT required the GC4419 dose to be reduced 1 dose level (ie, from 112 mg to 75 mg). Up to 2 such dose reductions per patient were permitted. Six patients per cohort were enrolled if DLT was observed in 1 of the first 3 patients. The maximum tolerated dose (MTD) of GC4419 was defined as the highest dose and longest schedule at which DLT was observed in >1 patient in a single dose and schedule cohort.

**Study assessments and analysis**

Adverse events were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

Oral mucositis was assessed by trained investigator-evaluators using WHO criteria, in which grade 0 = no mucositis; grade 1 = pain and erythema; grade 2 = ulceration, able to eat solid food; grade 3 = ulceration, able to consume only liquids; grade 4 = ulceration, inability to eat requiring tube or parenteral feeding. Oral mucositis was assessed twice weekly with at least a 48-hour interval between assessments during IMRT and weekly thereafter for up to 8 weeks or until the WHO score was <2. Oral mucositis assessment training and quality control were performed by Clinical Assistance Programs (Framingham, MA) to ensure that (1) all oral assessments were performed in a consistent manner using standardized questions, oral cavity examination technique and order, and data collection; and (2) WHO grade scoring was correctly assigned per assessment findings for all OM assessments. To reduce the variability in assessing a patient’s diet, investigator-evaluators were trained to carefully elucidate whether dietary compromise was due to oral pain. If not, and the diet was compromised by confounding factors (eg, dysgeusia, edentulous, nausea, mucus, throat pain, functional dysphagia), the WHO score was determined according to what the patient said he or she could eat absent these confounding factors.

Plasma concentrations of GC4419 and major metabolites were measured, using a validated liquid chromatography/mass spectrometry method, before infusion, at the end of infusion, and 1, 2, 4, and 6 to 8 hours after infusion with 2 dosing cycles: week 1/day 2, and day 3 during the last week of the infusion schedule.

Tumor status was assessed by clinical examination at the end of IMRT and 3, 6, 9, and 12 months thereafter. Standard-of-care imaging (computed tomography, positron emission tomography, or magnetic resonance imaging) was...
done before and 3 and 12 months after IMRT. After completion of the 12-month assessment, study follow-up ended.

Statistical analysis of clinical endpoints was descriptive. Severe OM incidence, time to onset, and duration were tabulated. Patients who never developed OM grade >2 had values of 0 days and >50 days imputed for duration and onset, respectively, of severe OM. Pharmacokinetics were analyzed by noncompartmental analysis using the software program Phoenix (WinNonlin Professional version 6.4; PharSight, Mountain View, CA).

Results

Nine US centers enrolled 46 patients between August 2013 and June 2015. Patient characteristics are summarized in Table 1. Forty-three patients completed OM assessments and were considered evaluable for OM; 44 completed tumor follow-up through 1 year after IMRT and were evaluable for tumor endpoints (Table 2).

Safety

Initial cohorts received GC4419 for the first 14 days of IMRT at 15 mg (n = 4), 30 mg (n = 3), 50 mg (n = 4), 75 mg (n = 3), or 112 mg (n = 6). In these 5 cohorts, 1 toxicity event—grade 3 nausea occurring at 112 mg—was considered potentially drug-related and therefore dose limiting. Ten of the 20 patients in these 5 cohorts completed treatment with no severe OM (Fig. 1). On the basis of the favorable tolerability profile of GC4419 in these cohorts, GC4419 dosing duration was extended by protocol amendment, initially in 3 serial cohorts at 112 mg/20 doses/4 weeks, 25 doses/5 weeks, or 30 doses/6 weeks (n = 3 each). In these 3 cohorts, one patient in the 112 mg/6 weeks cohort had grade 3 nausea, which was considered dose limiting. Because no single cohort had >1 patient with DLT, the MTD was not considered exceeded. However, to reduce the potential risk of nausea, the GC4419 dose was lowered in the next 2 additional cohorts, to 90 mg for 30 doses/6 weeks (n = 4), and then 35 doses/7 weeks (n = 6). Concurrently, another cohort received 30 mg for 35 doses/7 weeks (n = 4).

Of 46 patients, 41 (89%) received all planned GC4419 infusions. Five patients, all at 112 mg, stopped GC4419 early for adverse events (n = 2) or patient request (n = 3), receiving 2 of 14, 3 of 14, 9 of 14, 10 of 30, or 26 of 30 infusions. One additional patient (112 mg × 30 doses) had a permanent reduction to 75 mg for the last 6 doses.

### Table 1 Patient characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total patients enrolled</td>
<td>46</td>
</tr>
<tr>
<td>Men/women</td>
<td>38/8</td>
</tr>
<tr>
<td>Age (y), median (range)</td>
<td>58.5 (37-81)</td>
</tr>
<tr>
<td>Primary tumor</td>
<td></td>
</tr>
<tr>
<td>Oral cavity</td>
<td>7</td>
</tr>
<tr>
<td>Oropharyngeal</td>
<td>38</td>
</tr>
<tr>
<td>Unknown</td>
<td>1</td>
</tr>
<tr>
<td>Postoperative/definitive treatment</td>
<td>18/28</td>
</tr>
<tr>
<td>Overall stage</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>2</td>
</tr>
<tr>
<td>IVA</td>
<td>39</td>
</tr>
<tr>
<td>IVB</td>
<td>4</td>
</tr>
<tr>
<td>Not available</td>
<td>1</td>
</tr>
<tr>
<td>Tumor HPV status</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>25</td>
</tr>
<tr>
<td>Negative</td>
<td>2</td>
</tr>
<tr>
<td>Not available</td>
<td>19</td>
</tr>
<tr>
<td>Cisplatin schedule</td>
<td></td>
</tr>
<tr>
<td>Every 3 wk</td>
<td>39</td>
</tr>
<tr>
<td>Weekly</td>
<td>7</td>
</tr>
<tr>
<td>Evaluable for OM assessment</td>
<td>43</td>
</tr>
<tr>
<td>Evaluable for tumor follow-up</td>
<td>44</td>
</tr>
</tbody>
</table>

**Abbreviations:** HPV = human papillomavirus; OM = oral mucositis.

Values are number unless otherwise noted.

### Table 2 Distribution of patients by dose cohort

<table>
<thead>
<tr>
<th>Dose cohort</th>
<th>No. enrolled</th>
<th>No. evaluable for safety</th>
<th>No. evaluable for OM</th>
<th>No. evaluable for recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 mg/d × 14 doses</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>30 mg/d × 14 doses</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>50 mg/d × 14 doses</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>75 mg/d × 14 doses</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>112 mg/d × 14 doses</td>
<td>8</td>
<td>8</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>112 mg/d × 20 doses</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>112 mg/d × 25 doses</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>112 mg/d × 30 doses</td>
<td>5</td>
<td>5</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>90 mg/d × 30 doses</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>90 mg/d × 35 doses</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>30 mg/d × 35 doses</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
</tbody>
</table>

Totals: 46 46 43 44

* Two patients enrolled at 112 mg × 14 doses withdrew early, and two additional patients were enrolled in that cohort to complete safety and efficacy analysis.

1 One patient was analyzed with the 90 mg/d × 30 doses cohort and 1 patient limited OM evaluation to once weekly and thus was excluded from OM analysis.

1 One patient enrolled at 112 mg/d × 30 doses actually received 87 mg/d, per protocol provision, and is included with others at 90 mg/d × 30 doses in OM analysis.

Abbreviation as in Table 1.
because of grade 3 nausea; the other 40 received their full doses.

The median total radiation therapy dose was 70 Gy (<10 Gy for 2 early-withdrawing patients, 81.3 Gy for 1 patient, 66-70 Gy for all others). Radiation therapy breaks of 5 or more consecutive fractions occurred in 3 of 46 patients (6.5%) (attributed to grade 3 nausea; respiratory failure unrelated to GC4419; patient noncompliance). A total of 9 patients (1 at 15 mg of GC4419, 2 at 30 mg, 3 at 90 mg, 3 at 112 mg), all receiving every-3-week platinum, had their platinum doses reduced by 20% to 60% for the second and/or third scheduled dose, at the discretion of the treating investigator, because of adverse events attributed to cisplatin. Four of the 9 patients received the full schedule of GC4419 (1 30 mg/d × 35 doses, 2 90 mg/d × 35 doses, and 1 90 mg/d × 30 doses), and another 3 of the 9 patients received 112 mg/d (1 × 14 doses, 1 × 20 doses, and 1 × 30 doses).

Overall, adverse events, the most common of which were cytopenias, nausea, fatigue, constipation, dysgeusia, and dry mouth, were considered attributable to IMRT/cisplatin, complications of HNSCC, or other concomitant conditions. Although dose escalation of GC4419 was curtailed before reaching a formal MTD, grade 3 nausea or vomiting was more frequent at higher GC4419 doses (Table 3), as was transient, infusion-related grade 1 facial paresthesia that spontaneously resolved shortly after the infusion and did not limit dosing.
OM efficacy

For patients who received 30 or 90 mg over the full 6 to 7 weeks of CRT, the cumulative incidence of severe OM was 29% (4 of 14) through 6 weeks of RT (60 Gy), and 50% (7 of 14) at any time, with a median time to onset >50 days, and a median duration of 2.5 days (Fig. 1, Table 4). In contrast, in the initial 5 cohorts, GC4419 for 3 weeks was not as effective in reducing cumulative severe OM through 60 Gy (incidence 40% and duration 4.5 days).

For patients in the intermediate treatment group, cumulative incidence at 60 Gy was 44%, at any time 67%, median onset 43 days, and duration 18 days. Duration of all grades of OM seemed to be shorter as GC4419 administration was extended further in the IMRT treatment period (Fig. 2).

Pharmacokinetics

Peak concentration and area under the concentration time profile were approximately dose-proportional for GC4419 in plasma (data not shown). The terminal elimination half-life was approximately 2 hours, with minimal accumulation upon repeated dosing. There were 2 primary metabolites: the major metabolite GC4520/parent GC4419 ratio was approximately 10% at all dose levels, and the minor metabolite GC4570/GC4419 ratio was <0.2% (data not shown).

Tumor outcomes

Of 46 patients, 44 were evaluable for the 1-year tumor outcome analysis (2 patients withdrew consent for follow-up; Table 5). Per study design, post-radiation therapy follow-up was completed through 12 months for all 44 patients. Three patients died during the follow-up phase: 2 patients with oropharyngeal cancer died of noncancer causes without evidence of progression, and 1 patient with oropharyngeal cancer (human papillomavirus [HPV] negative) died from locoregional and distant recurrence at 6 months. Two additional patients with oropharyngeal cancer

Table 3

<table>
<thead>
<tr>
<th>Parameter</th>
<th>15 mg daily</th>
<th>30 mg daily</th>
<th>50 mg daily</th>
<th>75 mg daily</th>
<th>90 mg daily</th>
<th>14 or 35 total doses*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>14 total doses</td>
<td>14 total doses</td>
<td>35 total doses</td>
<td>14 or 35 total doses</td>
<td>14 total doses</td>
<td>30 total doses</td>
</tr>
<tr>
<td>N Paresthesia (grade 1)</td>
<td>4</td>
<td>3</td>
<td>4</td>
<td>7</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Nausea (grade 3)</td>
<td>0</td>
<td>0</td>
<td>1 (25)</td>
<td>1 (14)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Vomiting (grade 3)</td>
<td>0</td>
<td>0</td>
<td>1 (25)</td>
<td>1 (14)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Nausea (any grade)</td>
<td>4 (100)</td>
<td>2 (67)</td>
<td>4 (100)</td>
<td>6 (86)</td>
<td>4 (100)</td>
<td>2 (67)</td>
</tr>
</tbody>
</table>

* Values are number (percentage). Tabulated events are listed without regard to attribution to GC4419.

A total of 5 patients—3 in the 112 mg/14 dose cohort, and 2 in the 112 mg/30 dose cohort—received fewer infusions than planned, and 1 in the 112 mg/30 dose cohort had a permanent dose reduction to 75 mg. Also, one patient enrolled at 112 mg × 30 doses received 87 mg per protocol and is summarized with the 90 mg × 30 dose cohort in this table. See text.

Table 4

<table>
<thead>
<tr>
<th>Severe OM (grades 3 and 4)</th>
<th>Comparative historical control</th>
<th>GC4419 phase Ib/2a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unpublished data</td>
<td>Placebo data from phase 3 trials</td>
<td>Partial treatment (3 wk) (n = 20)</td>
</tr>
<tr>
<td>S. Sonis (n = 380)</td>
<td>Le et al (3) (n = 94)</td>
<td>Henke et al (2) (n = 94)</td>
</tr>
</tbody>
</table>

Incidence (%)  
Through 60 Gy  
At any time  
Onset (d), median (range)  
Duration (d), median (range)  

Abbreviation as in Table 1.

Results for the 14 patients receiving 30 or 90 mg for 6-7 weeks are compared with those in the initial dose escalation phase (n = 20), the intermediate schedule (n = 9), and representative historical controls. Patients who never developed OM of grade >2 had values of 0 days and >50 days imputed for duration and onset, respectively, of severe (grade 3-4) OM.
had locoregional progression at month 12 (1 HPV positive and 1 HPV unknown), and 3 patients had distant metastases at month 12. One of the 5 patients who experienced recurrence was in the full-dose cohort (90 mg/C235 doses). None of the 5 patients who experienced recurrence required cisplatin dose reduction. Two of the 5 patients received 2 full doses of cisplatin 100 mg/m² but missed the last every-3-weeks dose of cisplatin, 1 owing to patient noncompliance and 1 owing to “administrative reasons.”

Discussion

In this study we found it feasible to add the SOD mimetic GC4419 to IMRT and cisplatin. Observed safety was acceptable at all dose and duration schedules studied. Delivery of planned CRT was not compromised in the presence of GC4419. Grade 3 nausea and vomiting were more frequent at the highest dose (112 mg). Because of this, and a low threshold for additional toxicity in this patient population, GC4419 dose escalation was curtailed before reaching the study-defined MTD. The most common GC4419-associated adverse event—mild paresthesia—is similar to reports with sublingual nitroglycerine (28) and is likely due to potentiation of nitric oxide (NO) by GC4419, as has previously been reported to occur with this class of compounds (29). Superoxide reacts rapidly with NO to remove it, and abruptly reducing the amount of superoxide present would be expected to potentiate NO’s effects.

The anticipated incidence, duration, and time to onset of severe OM in this study were favorable compared with historical controls (Table 4). These controls included the placebo arms of 2 published studies of palifermin (2, 3) and unpublished results known to one of the authors (Sonis) from control arms of multiple prospective OM studies. The unpublished historical controls are not case-matched with the present study, and stage and HPV status are not available. The unpublished experience was limited to patients with oral cavity or oropharyngeal primaries, postoperative and definitive, who received IMRT plus concurrent cisplatin (every 3 weeks or weekly). However, for all of these published and unpublished historical data, mucositis was assessed at sites receiving >50 Gy by the same OM assessment criteria (trained assessors, assessment method, assessment interval, WHO scale) as in the present trial. Although conclusions from historical, cross-study comparisons must be limited, the present results are sufficiently encouraging to warrant more rigorous assessment in a prospective controlled trial.

Oral mucositis results were best for the cohorts that received 30 or 90 mg of GC4419 for 6 to 7 weeks, consistent with expectations that GC4419 should be administered throughout the entire IMRT course to remove superoxide produced with each IMRT fraction. Patients receiving as little as 30 mg of GC4419 had little severe OM (Fig. 1). Further, OM results through 6 weeks/60 Gy are of interest because this is a common landmark expected to be reached in IMRT of all patients with locally advanced HNSCC.

Although most of our patients developed OM of WHO grade ≥2, consistent with prior reports (4), severe (WHO grade 3-4) OM is arguably more relevant to clinical benefit. Reducing severe OM should decrease the substantial day-
to-day burden of OM overall (5). As a result, increased resource usage estimated to cost approximately $18,000 per patient (10) could be reduced. A further question is whether patients’ subjective reports of mouth and throat soreness correspond to the WHO score, a relationship that held for palifermin’s effects on OM in patients receiving total body irradiation/high-dose chemotherapy and hematopoietic stem cell transplant (30) but not in the trials of that drug in HNSCC patients (2, 3).

Of equal importance, IMRT treatment breaks are associated with compromised tumor outcomes in HNSCC (7, 8). That only 3 of 46 patients (6.5%) in this study had radiation therapy breaks of 5 or more consecutive fractions is promising. Treatment breaks of this duration were reported in 15% of both control and experimental patients in the 2 palifermin studies to reduce OM in HNSCC (2, 3), which used 3-field conformal radiation, and 15.1% of patients receiving IMRT/platinum and 26.9% receiving IMRT/cetuximab in the Radiation Therapy Oncology Group 0522 trial (31).

For cancer supportive care agents, a major concern is that they not compromise or antagonize the efficacy of the underlying antitumor regimen. In the present study tumor outcomes at 1 year did not seem unfavorable compared with contemporary expectations (31), but conclusions are limited owing to the small sample size and lack of a placebo arm for control.

On a mechanistic basis, GC4419 is expected not to antagonize, but instead potentially enhance, tumor radiation response. Normal and cancer cells metabolize reactive oxygen species differently. Specifically, normal cells tend to be more sensitive to elevations in superoxide anion but more tolerant of increases in hydrogen peroxide flux. They utilize redox protective enzyme systems to convert superoxide into water and molecular oxygen, removing it rapidly to prevent normal tissue damage. Although these same enzyme systems are typically active in cancer cells, moderate elevations in superoxide actually serve to promote tumor growth, but significant increases in hydrogen peroxide flux are apparently less well tolerated than for normal cells (32). Thus, therapeutic radiation, by increasing superoxide, can overwhelm the SOD enzyme system and initiate normal tissue toxicity such as OM. GC4419 can convert this excess superoxide into hydrogen peroxide, which is less toxic to normal tissue, while simultaneously maintaining or even increasing antitumor efficacy. Consistent with this are nonclinical data demonstrating synergy, especially between GC4419 and higher dose-fraction RT regimes (27), as are becoming used in stereotactic body radiation therapy.

To our knowledge this is the first clinical trial of a selective SOD mimetic to reduce radiation therapy–induced severe OM. Results in animal models of radiation OM have been reported for a manganese SOD (33), for nonselective oxygen radical scavengers (34), and for manganese porphyrins that mimic both SOD and catalase (35). None of these, however, has been tested in a clinical study of OM. A marketed bovine-sourced copper-zinc SOD was also tested in a small study of head and neck cancer patients for treatment of radiation toxicities in head and neck cancer patients (36), but that product was subsequently withdrawn from all markets for safety reasons.

The promising OM results of this study, along with a comparative assessment of the contribution of GC4419 to the toxicity and tumor control outcomes of CRT, must be confirmed in a larger randomized, placebo-controlled setting. To that end, doses of 30 and 90 mg/d administered throughout CRT were selected for the randomized, double-blind, placebo-controlled GC4419 phase 2b trial in progress. Tumor follow-up will extend through 24 months after IMRT in that trial.

References


